The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells

Clinical Immunology

Volumn 158, Issue 1, 2015, Pages 67-76

  Yang, Yang ^a   Tang, Qian ^a   Zhao, Ming ^a   Liang, Gongping ^a   Wu, Haijing ^a   Li, Duo ^a   Xie, Yubing ^b   Tan, Yixin ^a   Dai, Yong ^c   Yung, Susan ^d   Chan, Tak Mao ^d   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Changsha Blood Center   (China)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CD40L; CD4+T cells; Epigenetics; Mycophenolic acid; Systemic lupus erythematosus

Indexed keywords

CD40 LIGAND; CD70 ANTIGEN; E1A ASSOCIATED P300 PROTEIN; GENOMIC DNA; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN G; INTERLEUKIN 17F; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID; SIRTUIN 1; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE; MESSENGER RNA;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME INHIBITION; EPIGENETICS; FEMALE; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; UPREGULATION; ACETYLATION; CASE CONTROL STUDY; CELL CULTURE; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; METABOLISM; METHYLATION; YOUNG ADULT;

ACETYLATION; ADULT; ANTIGENS, CD11A; ANTIGENS, CD70; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELLS, CULTURED; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLATION; MIDDLE AGED; MYCOPHENOLIC ACID; RNA, MESSENGER; YOUNG ADULT;

EID: 84928340468     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.005     Document Type: Article

References (40)

1. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118.
2. Oglesby A., Shaul A.J., Pokora T., Paramore C., Cragin L., Dennis G., Narayanan S., Weinstein A. Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int. J. Rheumatol. 2013, 2013:347520.
3. Wolffe A.P., Matzke M.A. Epigenetics: regulation through repression. Science (New York, N.Y.) 1999, 286:481-486.
4. Hedrich C.M., Crispin J.C., Tsokos G.C. Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity 2014, 47:234-241.
5. Miao C.G., Yang J.T., Yang Y.Y., Du C.L., Huang C., Huang Y., Zhang L., Lv X.W., Jin Y., Li J. Critical role of DNA methylation in the pathogenesis of systemic lupus erythematosus: new advances and future challenges. Lupus 2014, 23:730-742.
6. Pan Y., Sawalha A.H. Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl. Res. 2009, 153:4-10.
7. Hu N., Qiu X., Luo Y., Yuan J., Li Y., Lei W., Zhang G., Zhou Y., Su Y., Lu Q. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 2008, 35:804-810.
8. Zhang Y., Zhao M., Sawalha A.H., Richardson B., Lu Q. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J. Autoimmun. 2013, 41:92-99.
9. Lu Q., Kaplan M., Ray D., Ray D., Zacharek S., Gutsch D., Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 2002, 46:1282-1291.
10. Lu Q., Wu A., Richardson B.C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 2005, 174:6212-6219.
11. Zhou Y., Yuan J., Pan Y., Fei Y., Qiu X., Hu N., Luo Y., Lei W., Li Y., Long H., Sawalha A.H., Richardson B., Lu Q. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin. Immunol. 2009, 132:362-370.
12. Butler J.S., Koutelou E., Schibler A.C., Dent S.Y. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics 2012, 4:163-177.
13. Garcia B.A., Busby S.A., Shabanowitz J., Hunt D.F., Mishra N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 2005, 4:2032-2042.
14. Zhao M., Wu X., Zhang Q., Luo S., Liang G., Su Y., Tan Y., Lu Q. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res. Ther. 2010, 12:R227.
15. Jeffries M.A., Sawalha A.H. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int. J. Clin. Rheumatol. 2011, 6:423-439.
16. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 2007, 179:6352-6358.
17. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
18. Costa-Reis P., Sullivan K.E. Genetics and epigenetics of systemic lupus erythematosus. Curr. Rheumatol. Rep. 2013, 15:369.
19. Frangou E.A., Bertsias G.K., Boumpas D.T. Gene expression and regulation in systemic lupus erythematosus. Eur. J. Clin. Investig. 2013, 43:1084-1096.
20. Furukawa H., Oka S., Matsui T., Hashimoto A., Arinuma Y., Komiya A., Fukui N., Tsuchiya N., Tohma S. Genome, epigenome and transcriptome analyses of a pair of monozygotic twins discordant for systemic lupus erythematosus. Hum. Immunol. 2013, 74:170-175.
21. Ikeuchi H., Hiromura K., Takahashi S., Mishima K., Sakurai N., Sakairi T., Kaneko Y., Maeshima A., Kuroiwa T., Nojima Y. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod. Rheumatol. 2013, 24:618-625.
22. Jourde-Chiche N., Chiche L., Mancini J., Daniel L., Bardin N., Burtey S., Gondouin B., Dussol B., Harle J.R., Hamidou M., Meulders Q., Daugas E. Proliferative lupus nephritis treatment: practice survey in nephrology and internal medicine in France. Nephrol. Ther. 2014, 10:170-176.
23. Liu A., La Cava A. Epigenetic dysregulation in systemic lupus erythematosus. Autoimmunity 2014, 47:215-219.
24. Verdone L., Agricola E., Caserta M., Di Mauro E. Histone acetylation in gene regulation. Brief. Funct. Genomic Proteomic 2006, 5:209-221.
25. Mishra N., Brown D.R., Olorenshaw I.M., Kammer G.M. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2628-2633.
26. Sasaki K., Yoshida M. [Histone modification enzymes]. Tanpakushitsu Kakusan Koso 2006, 51:2069-2075.
27. Trapp J., Jung M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr. Drug Targets 2006, 7:1553-1560.
28. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
29. Verdin E., Dequiedt F., Kasler H. HDAC7 regulates apoptosis in developing thymocytes. Novartis Found. Symp. 2004, 259:115-129. (discussion 129-131, 163-119).
30. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., Adcock I.M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 2006, 203:7-13.
31. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
32. Hogg N., Laschinger M., Giles K., McDowall A. T-cell integrins: more than just sticking points. J. Cell Sci. 2003, 116:4695-4705.
33. Arens R., Nolte M.A., Tesselaar K., Heemskerk B., Reedquist K.A., van Lier R.A., van Oers M.H. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 2004, 173:3901-3908.
34. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 1996, 97:2063-2073.
35. Peters A.L., Stunz L.L., Bishop G.A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 2009, 21:293-300.
36. Lockshin M.D. Sex ratio and rheumatic disease: excerpts from an Institute of Medicine report. Lupus 2002, 11:662-666.
37. Anolik J.H., Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies best practice & research. Clin. Rheumatol. 2005, 19:859-878.
38. Vincent F.B., Northcott M., Hoi A., Mackay F., Morand E.F. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res. Ther. 2013, 15:R97.
39. Zhao X.F., Pan H.F., Yuan H., Zhang W.H., Li X.P., Wang G.H., Wu G.C., Su H., Pan F.M., Li W.X., Li L.H., Chen G.P., Ye D.Q. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. 2010, 37:81-85.
40. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183:3160-3169.